Galecto Begins Patient Enrollment In Phase 2 Trial Of Gb1211 In Combo With Atezolizumab To Treat Nsclc

Galecto, Inc., A Clinical Stage Biotechnology Company, Announced That The First Patient Has Been Enrolled In The Phase 2A Gallant-1 Trial (Nct05240131).Gallant-1 Is Designed To Study The Combination Of Gb1211, Galecto